Hospital
ST. John's Riverside Hospital
ST. John's Riverside Hospital was paid $66.29M by Medicaid between Jan 2018 and Dec 2024, across 300 billing codes. Its largest line is H0020, Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) — 14% of everything it billed.
33Billing provider infoST. JOHN'S RIVERSIDE HOSPITAL
YONKERS, NY 10701
YONKERS, NY 10701
33aNPI1578526695assigned 04/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$66.29M
24GClaims1,095,339
24DCodes billed300
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#24 of 231
Median peer was paid$561K
This provider vs. median118×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,355 | $1.07M | |
| 2019 | 88,375 | $4.68M | |
| 2020 | 192,412 | $9.91M | |
| 2021 | 222,318 | $11.79M | |
| 2022 | 197,444 | $15.06M | |
| 2023 | 219,145 | $15.22M | |
| 2024incomplete | 155,290 | $8.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 14% | 282,366 | 15,077 | $8.99M |
| H2036 | Alcohol and/or other drug treatment program, per diem | 9.2% | 46,431 | 6,221 | $6.09M |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 8.0% | 77,580 | 12,117 | $5.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 20,892 | 20,040 | $4.98M |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 6.6% | 35,282 | 14,894 | $4.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.2% | 17,224 | 16,451 | $3.45M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 3.0% | 33,426 | 13,965 | $1.97M |
| H2001 | Rehabilitation program, per 1/2 day | 2.6% | 16,373 | 4,877 | $1.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 10,090 | 9,755 | $1.66M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 8,083 | 7,607 | $1.42M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.1% | 9,213 | 7,424 | $1.39M |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 53,443 | 42,022 | $1.26M |
288 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 33,277 | $1.23M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 9,587 | $1.20M |
| HZ2ZZZZ | 1.7% | 2,969 | $1.10M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 5,856 | $1.10M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 1.6% | 5,004 | $1.05M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 3,507 | $985K |
| 81025 | 1.3% | 1,709 | $829K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 7,619 | $769K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 2,948 | $757K |
| HZ42ZZZ | 1.1% | 615 | $726K | |
| 50590 | <1% | 317 | $621K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,386 | $572K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,406 | $511K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 3,002 | $496K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,412 | $485K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,078 | $466K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,319 | $457K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,725 | $405K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,260 | $393K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,911 | $379K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 1,513 | $327K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,099 | $326K |
| 59025 | Fetal non-stress test | <1% | 1,732 | $311K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,302 | $308K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 291 | $259K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 938 | $258K |
| 97010 | <1% | 8,627 | $250K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 885 | $242K |
| 99442 | <1% | 1,267 | $237K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,002 | $228K |
| 76830 | Ultrasound, transvaginal | <1% | 3,007 | $227K |
| 86850 | <1% | 5,339 | $199K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,762 | $193K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,617 | $181K |
| 88342 | <1% | 408 | $179K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,650 | $179K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,404 | $161K |
| 93970 | <1% | 434 | $158K | |
| 76641 | <1% | 2,702 | $151K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,851 | $150K |
| 86900 | <1% | 5,384 | $147K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,066 | $137K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 102 | $129K |
| 86901 | <1% | 5,348 | $122K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,493 | $120K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,818 | $118K |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 1,936 | $112K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,240 | $109K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,764 | $109K |
| 71250 | <1% | 1,003 | $105K | |
| 74178 | <1% | 509 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,206 | $98K |
| 97161 | <1% | 1,067 | $98K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,347 | $95K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,380 | $94K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 1,688 | $88K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 136 | $86K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 134 | $85K |
| T1006 | Alcohol and/or substance abuse services, family/couple counseling | <1% | 693 | $84K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 271 | $84K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,179 | $78K |
| 93017 | <1% | 780 | $78K | |
| G0378 | Hospital observation service, per hour | <1% | 1,599 | $77K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,362 | $76K |
| 76536 | <1% | 1,461 | $72K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,172 | $68K |
| 80061 | Lipid panel | <1% | 6,710 | $62K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 390 | $60K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 39 | $58K |
| 76775 | <1% | 1,224 | $58K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,645 | $58K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,024 | $56K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 212 | $56K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 3,735 | $53K |
| 86480 | <1% | 1,283 | $49K | |
| 76000 | <1% | 1,199 | $45K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 917 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,716 | $41K |
| 72141 | <1% | 133 | $38K | |
| 72100 | <1% | 1,479 | $38K | |
| 93971 | <1% | 395 | $37K | |
| 86359 | <1% | 1,794 | $36K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 162 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,913 | $35K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,838 | $32K |
| 99243 | <1% | 223 | $32K | |
| 77080 | <1% | 474 | $29K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $28K |
| 77065 | Tomosynthesis, mammo | <1% | 357 | $27K |
| 99441 | <1% | 202 | $27K | |
| 86780 | <1% | 3,022 | $25K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,813 | $24K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,355 | $23K |
| 90715 | <1% | 878 | $23K | |
| 84703 | <1% | 7,868 | $23K | |
| 99406 | <1% | 668 | $23K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 146 | $23K |
| 86360 | <1% | 1,871 | $22K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,776 | $22K |
| 87517 | <1% | 941 | $22K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,939 | $21K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,700 | $20K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 571 | $19K |
| 54161 | <1% | 16 | $19K | |
| 76801 | <1% | 136 | $18K | |
| 83655 | <1% | 1,607 | $18K | |
| 99443 | <1% | 236 | $17K | |
| 77066 | Tomosynthesis, mammo | <1% | 200 | $17K |
| 76642 | <1% | 374 | $17K | |
| 97035 | <1% | 1,100 | $16K | |
| 85027 | <1% | 6,323 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,426 | $16K |
| 73630 | <1% | 1,936 | $16K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 66 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 502 | $15K |
| 84439 | <1% | 2,651 | $15K | |
| 73560 | <1% | 914 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,998 | $15K |
| 73030 | <1% | 1,105 | $14K | |
| 83880 | <1% | 498 | $14K | |
| 84702 | <1% | 2,650 | $13K | |
| 73221 | <1% | 46 | $13K | |
| 82962 | <1% | 4,153 | $13K | |
| 70486 | <1% | 145 | $12K | |
| 73610 | <1% | 1,350 | $12K | |
| 82378 | <1% | 895 | $12K | |
| 86803 | <1% | 2,490 | $12K | |
| 82803 | <1% | 365 | $11K | |
| 99401 | <1% | 270 | $11K | |
| 82728 | <1% | 1,407 | $10K | |
| 81003 | <1% | 15,786 | $10K | |
| 73130 | <1% | 1,179 | $10K | |
| 87340 | <1% | 1,865 | $10K | |
| 80076 | <1% | 2,615 | $10K | |
| Q3014 | Telehealth originating site facility fee | <1% | 420 | $10K |
| 82607 | <1% | 1,302 | $9K | |
| 97116 | <1% | 320 | $9K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,150 | $9K |
| 86769 | <1% | 300 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,000 | $8K |
| 88304 | <1% | 145 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 506 | $7K |
| 0012A | <1% | 269 | $7K | |
| 87536 | <1% | 1,441 | $7K | |
| 82670 | <1% | 330 | $7K | |
| 87070 | <1% | 2,089 | $7K | |
| 85610 | <1% | 6,413 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 38 | $6K |
| G2251 | Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion | <1% | 495 | $6K |
| 83001 | <1% | 418 | $6K | |
| 90656 | <1% | 199 | $6K | |
| 90849 | <1% | 74 | $5K | |
| 86301 | <1% | 434 | $5K | |
| 84153 | <1% | 569 | $5K | |
| 83735 | <1% | 5,150 | $5K | |
| 83550 | <1% | 1,363 | $5K | |
| 82465 | <1% | 1,436 | $5K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 215 | $5K |
| 94760 | <1% | 2,419 | $5K | |
| 83540 | <1% | 1,459 | $4K | |
| 83002 | <1% | 351 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 188 | $4K |
| 0011A | <1% | 286 | $4K | |
| 86038 | <1% | 868 | $4K | |
| 73562 | <1% | 556 | $4K | |
| 72050 | <1% | 139 | $4K | |
| 82550 | <1% | 3,030 | $4K | |
| 82553 | <1% | 908 | $4K | |
| 86140 | <1% | 1,657 | $4K | |
| 85730 | <1% | 4,224 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 139 | $4K |
| 97162 | <1% | 25 | $4K | |
| 74019 | <1% | 126 | $3K | |
| 84146 | <1% | 237 | $3K | |
| 84436 | <1% | 1,181 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,979 | $3K |
| 82977 | <1% | 822 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,327 | $3K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 12 | $3K |
| 86304 | <1% | 248 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,383 | $3K |
| 73110 | <1% | 408 | $3K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 209 | $3K |
| 86704 | <1% | 676 | $3K | |
| 83525 | <1% | 253 | $3K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 86 | $3K |
| 86708 | <1% | 641 | $3K | |
| 95806 | <1% | 15 | $2K | |
| 83690 | <1% | 4,523 | $2K | |
| 83516 | <1% | 271 | $2K | |
| 82570 | <1% | 689 | $2K | |
| 85651 | <1% | 1,614 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 12 | $2K |
| 73502 | <1% | 158 | $2K | |
| 96367 | <1% | 54 | $2K | |
| 84403 | <1% | 104 | $2K | |
| 82784 | <1% | 213 | $2K | |
| 86787 | <1% | 200 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $2K |
| 90882 | <1% | 81 | $2K | |
| 87186 | <1% | 1,476 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 19 | $2K |
| 84484 | <1% | 5,817 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 64 | $2K |
| 93925 | <1% | 12 | $2K | |
| 82172 | <1% | 135 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 56 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $1K |
| 83021 | <1% | 134 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,196 | $1K |
| 83010 | <1% | 181 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,798 | $1K |
| 90686 | <1% | 54 | $1K | |
| 81001 | <1% | 1,034 | $1K | |
| 82043 | <1% | 314 | $1K | |
| 86709 | <1% | 170 | $1K | |
| 86762 | <1% | 82 | $1K | |
| 83883 | <1% | 82 | $1K | |
| 84550 | <1% | 378 | $952.32 | |
| 86593 | <1% | 384 | $938.95 | |
| 99386 | <1% | 14 | $907.27 | |
| 86707 | <1% | 135 | $885.60 | |
| 82103 | <1% | 105 | $865.53 | |
| 76870 | <1% | 24 | $853.08 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 13 | $838.47 |
| 84402 | <1% | 49 | $807.76 | |
| 73070 | <1% | 84 | $762.97 | |
| 86705 | <1% | 127 | $746.69 | |
| 87350 | <1% | 119 | $741.47 | |
| 85660 | <1% | 256 | $737.08 | |
| 86706 | <1% | 137 | $724.39 | |
| 80050 | General health panel | <1% | 25 | $690.74 |
| 90863 | <1% | 65 | $674.28 | |
| 84100 | <1% | 1,684 | $652.53 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $650.93 |
| 87420 | <1% | 15 | $598.89 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $584.92 |
| 87040 | <1% | 473 | $547.00 | |
| 84479 | <1% | 412 | $543.73 | |
| 86747 | <1% | 36 | $541.88 | |
| 82247 | <1% | 275 | $525.87 | |
| 83721 | <1% | 1,757 | $515.45 | |
| 0031A | <1% | 40 | $485.63 | |
| 82390 | <1% | 79 | $448.88 | |
| 87807 | <1% | 890 | $386.81 | |
| 82150 | <1% | 246 | $381.76 | |
| 82947 | <1% | 246 | $372.33 | |
| 96376 | <1% | 116 | $371.80 | |
| 87077 | <1% | 471 | $337.51 | |
| 82272 | <1% | 208 | $327.50 | |
| 84481 | <1% | 40 | $312.46 | |
| 83615 | <1% | 145 | $292.11 | |
| 82248 | <1% | 84 | $278.98 | |
| 0002A | <1% | 14 | $238.75 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 283 | $230.22 |
| 84478 | <1% | 133 | $229.08 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 100 | $229.06 |
| 72070 | <1% | 12 | $214.88 | |
| 73523 | <1% | 12 | $213.61 | |
| 86317 | <1% | 55 | $195.44 | |
| 82105 | <1% | 59 | $185.25 | |
| 74018 | <1% | 14 | $181.60 | |
| 86376 | <1% | 12 | $164.77 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 15 | $163.05 |
| 97124 | <1% | 59 | $153.85 | |
| 86431 | <1% | 56 | $151.23 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,418 | $150.74 |
| 87430 | <1% | 226 | $150.54 | |
| 87205 | <1% | 398 | $147.41 | |
| 0001A | <1% | 12 | $143.57 | |
| 86618 | <1% | 12 | $142.27 | |
| 82565 | <1% | 66 | $140.01 | |
| 82746 | <1% | 25 | $137.78 | |
| 86765 | <1% | 12 | $124.79 | |
| 82950 | <1% | 27 | $107.65 | |
| 84460 | <1% | 151 | $101.93 | |
| 84450 | <1% | 144 | $100.39 | |
| 83605 | <1% | 761 | $93.62 | |
| 73590 | <1% | 12 | $79.74 | |
| 85045 | <1% | 41 | $71.77 | |
| 85379 | <1% | 388 | $61.17 | |
| 84156 | <1% | 15 | $43.67 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 67 | $35.00 |
| 84520 | <1% | 12 | $23.44 | |
| 85044 | <1% | 13 | $17.93 | |
| 73140 | <1% | 39 | $12.00 | |
| 91301 | <1% | 81 | $0.18 | |
| 99080 | 0% | 2,727 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialATTANASIO, GLADYS (AVP REV CYCLE)